Eptinezumab for Migraine Prevention in Patients 50 Years or Older: A Subgroup Analysis of PROMISE-1 and PROMISE-2

被引：0
|
作者：
Martin, V. [1 ]
Tassorelli, C. [2 ]
Ettrup, A. [3 ]
Hirman, J. [4 ]
Cady, R. [5 ]
机构：
[1] UC Headache & Facial Pain Ctr, Cincinnati, OH USA
[2] IRCCS C Mondino Fdn, Pavia, Italy
[3] H Lundbeck & Co AS, Copenhagen, Denmark
[4] Pacific Northwest Stat Consulting Inc, Woodinville, WA USA
[5] Lundbeck La Jolla Res Ctr, San Diego, CA USA
来源：
CEPHALALGIA | 2021年 / 41卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0289
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [11] Consistent reductions in migraine frequency with eptinezumab treatment in patients with migraine stratified by intrinsic factors: subgroup analyses of PROMISE-1 and PROMISE-2
    Janelidze, Marina
    Giorgadze, Gvantsa
    Cady, Roger
    Snapinn, Steve
    Hirman, Joe
    Kassel, Eric
    JOURNAL OF HEADACHE AND PAIN, 2019, 20
  • [12] Migraine Response in Patients With Migraine Receiving Eptinezumab Treatment: Consistency Throughout the PROMISE-1 and PROMISE-2 Trials
    Silberstein, S. D.
    Mechtler, L. L.
    Berman, G.
    Cady, R.
    Hirman, J.
    Mehta, L.
    HEADACHE, 2020, 60 : 113 - 114
  • [13] Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
    Apelian, Rami
    Boyle, Lee
    Hirman, Joe
    Asher, Divya
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [14] Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
    Rami Apelian
    Lee Boyle
    Joe Hirman
    Divya Asher
    The Journal of Headache and Pain, 2022, 23
  • [15] Measuring dose-related efficacy of eptinezumab for migraine prevention: Post hoc analysis of PROMISE-1 and PROMISE-2
    Apelian, R. G.
    Boyle, L.
    Hirman, J.
    Asher, D.
    HEADACHE, 2022, 62 : 151 - 152
  • [16] Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis PROMISE-1 and PROMISE-2
    Ashina, M.
    McAllister, P.
    Cady, R.
    Hirman, J.
    Ettrup, A.
    HEADACHE, 2021, 61 : 123 - 123
  • [17] Efficacy and Safety of Eptinezumab in Patients With Migraine and Self-Reported Aura: Post Hoc Analysis PROMISE-1 and PROMISE-2
    Ashina, M.
    McAllister, P.
    Cady, R.
    Hirman, J.
    Ettrup, A.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 51 - 51
  • [18] Efficacy and Safety of Eptinezumab in Patients With Migraine and Self-Reported Aura: Post Hoc Analysis PROMISE-1 and PROMISE-2
    Ashina, M.
    McAllister, P.
    Cady, R.
    Hirman, J.
    Ettrup, A.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 77 - 77
  • [19] Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
    Ashina, Messoud
    McAllister, Peter
    Cady, Roger
    Hirman, Joe
    Ettrup, Anders
    CEPHALALGIA, 2022, 42 (08) : 696 - 704
  • [20] Migraine-Free Months in Patients with Episodic or Chronic Migraine Treated with Eptinezumab: Results from the PROMISE-1 and PROMISE-2 Trials
    Winner, P. K.
    McAllister, P.
    Cady, R.
    Snapinn, S.
    Hirman, J.
    Kassel, E.
    HEADACHE, 2019, 59 : 162 - 162
12345